-
Leerink Swann Reiterates Incyte (INCY) Outperform Rating
Wednesday, March 17, 2010 - 11:41amLeerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens". They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way...
Read More >> -
Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating
Thursday, February 18, 2010 - 10:53amLeerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating of Gilead Sciences, Inc. (Nasdaq: GILD). The Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo hosted a conference call with an HIV specialist who was also an investigator in the Gilead Sciences quad...
Read More >>
